SynCore Biotechnology Co.,Ltd 4192.TWO Stock
SynCore Biotechnology Co.,Ltd Price Chart
SynCore Biotechnology Co.,Ltd 4192.TWO Financial and Trading Overview
| SynCore Biotechnology Co.,Ltd stock price | 49.9 TWD |
| Previous Close | 17.6 TWD |
| Open | 17.15 TWD |
| Bid | 17.3 TWD x N/A |
| Ask | 17.35 TWD x N/A |
| Day's Range | 17.15 - 17.35 TWD |
| 52 Week Range | 17.15 - 36.8 TWD |
| Volume | 92K TWD |
| Avg. Volume | 66.75K TWD |
| Market Cap | 531.88M TWD |
| Beta (5Y Monthly) | 1.104452 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.31 TWD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
4192.TWO Valuation Measures
| Enterprise Value | 1.85B TWD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 32.834114 |
| Price/Book (mrq) | 8.908341 |
| Enterprise Value/Revenue | 114.235 |
| Enterprise Value/EBITDA | -10.418 |
Trading Information
SynCore Biotechnology Co.,Ltd Stock Price History
| Beta (5Y Monthly) | 1.104452 |
| 52-Week Change | -40.034% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 36.8 TWD |
| 52 Week Low | 17.15 TWD |
| 50-Day Moving Average | 18.84 TWD |
| 200-Day Moving Average | 24.35 TWD |
4192.TWO Share Statistics
| Avg. Volume (3 month) | 66.75K TWD |
| Avg. Daily Volume (10-Days) | 55K TWD |
| Shares Outstanding | 30.74M |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 66.92% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 267.16458:1000 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1067.36% |
| Gross Margin | 56.97% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -18.14% |
| Return on Equity (ttm) | -54.27% |
Income Statement
| Revenue (ttm) | 16.2M TWD |
| Revenue Per Share (ttm) | 0.14 TWD |
| Quarterly Revenue Growth (yoy) | 10.19% |
| Gross Profit (ttm) | 9.09M TWD |
| EBITDA | -177622000 TWD |
| Net Income Avi to Common (ttm) | -170228000 TWD |
| Diluted EPS (ttm) | -1.46 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 244.11M TWD |
| Total Cash Per Share (mrq) | 2.12 TWD |
| Total Debt (mrq) | 69.25M TWD |
| Total Debt/Equity (mrq) | 30.99 TWD |
| Current Ratio (mrq) | 1.786 |
| Book Value Per Share (mrq) | 1.942 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -171926000 TWD |
| Levered Free Cash Flow (ttm) | -111754248 TWD |
Profile of SynCore Biotechnology Co.,Ltd
| Country | Taiwan |
| State | N/A |
| City | Yilan City |
| Address | 84 Chung Shan Road |
| ZIP | 269 |
| Phone | 886 3 958 6101 |
| Website | https://www.syncorebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 50 |
SynCore Biotechnology Co.,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, and dermatology primarily in Taiwan. The company offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. It is also involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer;SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer;SB04 that is in Phase II clinical trials for the treatment of patients with dry age-related macular degeneration and SB05, a composition of cytostatic drug paclitaxel combined with neutral and positive lipids, which is in Phase III clinical trials for the treatment of patients with triple negative breast cancer and pancreatic cancer. The company has partnerships with Medigene AG; MacuCLEAR Inc.; Y-YBAR; Epipole Ltd.; Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes. The company was incorporated in 2008 and is headquartered in Yilan City, Taiwan. SynCore Biotechnology Co.,Ltd is a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Q&A For SynCore Biotechnology Co.,Ltd Stock
What is a current 4192.TWO stock price?
SynCore Biotechnology Co.,Ltd 4192.TWO stock price today per share is 49.9 TWD.
How to purchase SynCore Biotechnology Co.,Ltd stock?
You can buy 4192.TWO shares on the Taipei Exchange exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for SynCore Biotechnology Co.,Ltd?
The stock symbol or ticker of SynCore Biotechnology Co.,Ltd is 4192.TWO.
Which industry does the SynCore Biotechnology Co.,Ltd company belong to?
The SynCore Biotechnology Co.,Ltd industry is Biotechnology.
How many shares does SynCore Biotechnology Co.,Ltd have in circulation?
The max supply of SynCore Biotechnology Co.,Ltd shares is 35.17M.
What is SynCore Biotechnology Co.,Ltd Price to Earnings Ratio (PE Ratio)?
SynCore Biotechnology Co.,Ltd PE Ratio is now.
What was SynCore Biotechnology Co.,Ltd earnings per share over the trailing 12 months (TTM)?
SynCore Biotechnology Co.,Ltd EPS is -1.31 TWD over the trailing 12 months.
Which sector does the SynCore Biotechnology Co.,Ltd company belong to?
The SynCore Biotechnology Co.,Ltd sector is Healthcare.